TABLE 2.

Symptoms of chronic fatigue during all time intervals assessed retrospectively

	Prior to COVID‐19			0–4 weeks			4–12 weeks			>12 weeks			p‐value vs. baseline (men; women)*
	Men	Women	p‐value	Men	Women	p‐value	Men	Women	p‐value	Men	Women	p‐value	0–4 weeks	4–12 weeks	>12 weeks
1.1 Persistent fatigue, not caused by an effort, persisting after rest	13 (20.97)	59 (24.58)	0.551	48 (77.42)	214 (88.80)	0.020	41 (66.13)	191 (79.25)	0.030	29 (50.00)	148 (62.45)	0.083	<0.001; <0.001	<0.001; <0.001	<0.001; <0.001
1.2 Sore throat	2 (3.23)	12 (4.98)	0.742	14 (22.58)	88 (36.51)	0.039	5 (8.06)	47 (19.50)	0.037	3 (5.17)	21 (8.86)	0.434	0.001; <0.001	0.180; <0.001	0.563; 0.051
1.3 Self‐reported lymph node enlargement	1 (1.61)	8 (3.32)	0.691	5 (8.06)	43 (17.84)	0.078	3 (4.84)	32 (13.28)	0.075	0 (0.00)	14 (5.91)	0.080	0.102; <0.001	0.157; <0.001	0.317; 0.134
1.4 Myalgia	6 (9.68)	31 (12.86)	0.495	31 (50.00)	150 (62.24)	0.080	20 (32.26)	104 (43.15)	0.120	12 (20.69)	72 (30.38)	0.143	<0.001; <0.001	<0.001; <0.001	0.034; <0.001
1.5 Arthralgia	0 (0.00)	18 (7.47)	0.029	4 (6.45)	41 (17.01)	0.044	4 (6.45)	33 (13.69)	0.120	2 (3.45)	26 (10.97)	0.085	0.045; <0.001	0.046; 0.002	0.157; 0.102
1.6 Headache	9 (14.52)	60 (24.90)	0.082	32 (51.61)	177 (73.44)	<0.001	27 (43.55)	138 (57.26)	0.053	18 (31.03)	100 (42.19)	0.120	<0.001; <0.001	<0.001; <0.001	0.002; <0.001
1.7 Non‐restorative sleep	6 (9.68)	46 (19.09)	0.080	29 (46.77)	158 (65.56)	0.007	24 (38.71)	126 (52.28)	0.057	15 (25.86)	96 (40.51)	0.039	<0.001; <0.001	<0.001; <0.001	0.006; <0.001
1.8 Prolonged postexercise fatigue	6 (9.68)	42 (17.43)	0.137	43 (69.35)	195 (80.91)	0.048	39 (62.90)	160 (66.39)	0.607	23 (39.66)	119 (50.21)	0.149	<0.001; <0.001	<0.001; <0.001	<0.001; <0.001

Note: Data are presented as numbers (n) and percentages (%), *Cochran's Q test for dependent variable. The Bonferroni correction was used for pairwise comparisons, and the significance level was set below .008.